LAWRENCE, Mass. and PHILADELPHIA, Nov. 11, 2011 /PRNewswire/ -- Booth # 407 at The American Society of Nephrology (ASN)'s Kidney Week 2011 -- NxStage® Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that its Medisystems division has won a multi-year contract to supply the Vasc-Alert™ Access Surveillance Solution to Atlantic Dialysis Management Services centers.
"Robust access surveillance is increasingly important for outcomes, center economics, and compliance under the new bundled payment system. We believe Vasc-Alert's patented, automated technology simplifies and demonstrably improves a provider's ability to be effective in this area," said Mark Florence, Vice President & General Manager at Medisystems, a NxStage Company. "This agreement builds on a successful partnership between NxStage and Atlantic and demonstrates how Atlantic employs innovative new technology to improve patient care."
"After a thorough evaluation of Vasc-Alert, we believe we can reduce our rate of thrombectomy with this product technology," said J. Ganesh Bhat, M.D., Co-Principal, Atlantic Dialysis Management Services, L.L.C. "Vasc-Alert helps advance our goal of reducing hospitalizations and catheter usage. In addition, it provides a simple and convenient way to comply with CMS requirements for access surveillance without increasing staff workload."About Vasc-Alert Vasc-Alert, a patented medical device, uses computer technology to analyze standard treatment data taken during each patient's scheduled hemodialysis treatments to screen for vascular access dysfunction. By monitoring the data for increasing pressure trends, Vasc-Alert identifies patients who are at risk of developing a stenosis that may decrease the effectiveness of treatment or put the access site at risk of thrombosis -- a blockage that prevents the flow of blood through the access and can precipitate significant medical interventions such as thrombectomy and access revision. Weekly reports that identify at-risk patients are issued to the dialysis provider and allow the dialysis staff to proactively schedule further testing on the access. Earlier detection of access issues has the potential to lead to improved access patency, fewer hospitalizations, fewer missed treatments, and less pain, anxiety and inconvenience for patients.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts